Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%

MT Newswires Live

Yesterday

Amplia Therapeutics (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.

The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.

The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.

Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining "increasing attention" as a drug target in solid tumors, the filing added.

Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.

The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621255987"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621255987\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621255987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621255987","market":"hk","top_or_hot":-1,"title":"Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.</p><p>The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.</p><p>The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.</p><p>Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.</p><p>Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.</p><p>The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-23 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.</p><p>The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.</p><p>The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.</p><p>Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.</p><p>Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.</p><p>The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621255987","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621255987","pubTimestamp":1774233784,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research  in San Diego in April.The company's shares surged past 82% to reach their h","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4139":"生物科技"},"translate_title":"Amplia Therapeutics报告中位生存期为11.1个月，胰腺癌试验中有5项完全缓解，股价飙升82%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}